beryl drugs ltd
(524606:Bombay Stock Exchange)
beryl drugs ltd (524606) Snapshot
|
Open
--
|
Previous Close
--
|
|
|
Day High
--
|
Day Low
--
|
|
|
52 Week High
-- - --
|
52 Week Low
-- - --
|
|
|
Market Cap
--
|
Average Volume 10 Days
0.0
|
|
|
EPS TTM
--
|
Shares Outstanding
0.0
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
beryl drugs ltd (524606) Related Businessweek News
No Related Businessweek News Foundberyl drugs ltd (524606) Details
Beryl Drugs Ltd. engages in the manufacture, sale, and export of branded, generic pharmaceutical formulations in India and internationally. It offers I.V.fluids, and a range of small and large volume injectables. The company also provides a range of eye/ear drops, veterinary products, and injections. It sells its products through its sales and distribution network. In addition, the company offers research and development, as well as contract manufacturing services. Beryl Drugs Ltd. is based in Indore, India.
beryl drugs ltd (524606) Key Developments
Beryl Drugs Ltd. announced unaudited earnings results for the fourth quarter and full year ended March 31, 2013. For the quarter, the company reported income from sales was INR 38.379 million against INR 24.225 million a year ago. Profit from operations before other income, interest and tax was INR 0.260 million against profit of INR 1.804 million a year ago. Profit before tax was INR 0.526 million against profit of INR 1.468 million a year ago. Net profit was INR 0.426 million against profit of INR 1.068 million a year ago. Basic and diluted earnings per share were INR 0.08 against profit of INR 0.20 a year ago. For the year, the company reported income from sales was INR 173.291 million against INR 94.667 million a year ago. Profit from operations before other income, interest and tax was INR 8.314 million against profit of INR 1.889 million a year ago. Profit before tax was INR 8.501 million against profit of INR 1.246 million a year ago. Net profit was INR 7.701 million against profit of INR 0.884 million a year ago. Basic and diluted earnings per share were INR 1.50 against profit of INR 0.17 a year ago.
Beryl Drugs Ltd., Board Meeting, Apr 26, 2013. Agenda: To increase the remuneration of Sudhir Sethi, whole time director of the company and to increase the remuneration of Sanjay Sethi, managing director of the company.
Beryl Drugs Ltd. reported unaudited earnings results for the third quarter and nine months ended December 31, 2012. For the quarter, the company reported profit from operations before other income, interest and tax of INR 2.876 million compared to INR 1.793 million reported a year ago. Net profit was INR 2.516 million or INR 0.49 per basic and diluted share compared to net profit of INR 1.660 million or INR 0.32 per basic and diluted share reported a year ago. Income from sales was INR 45.284 million compared to INR 22.390 million reported a year ago. Profit before tax was INR 2.816 million against INR 1.760 million a year ago. For the nine months, the company reported profit from operations before other income, interest and tax of INR 8.114 million compared to INR 12.281 million reported a year ago. Net profit was INR 6.375 million or INR 1.24 per basic and diluted share compared to net profit of INR 10.750 million or INR 2.10 per basic and diluted share reported a year ago. Income from sales was INR 134.912 million compared to INR 72.573 million reported a year ago. Profit before tax was INR 7.975 million against INR 1.250 million a year ago.
| Recently Viewed | |||
| BRD:IN | 26.45 INR | 0.00 | |
| Company | Last | Change | |
| No competitor information is available for 524606. | |||
| View Industry Companies | |||
Industry Analysis
524606
Industry Average
| Valuation | 524606 | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.9x |
|
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
To contact BERYL DRUGS LTD, please visit www.beryldrugs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








